• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Po-05-185 prediction and risk of atrial fibrillation in patients with hypertrophic cardiomyopathy: a danish nationwide cohort study
Hypertrophic cardiomyopathy (HCM) can be associated with serious complications such as heart failure, atrial fibrillation (AF) and sudden cardiac death. The treatment of AF in HCM patients can be challenging since AF often aggravates symptoms and increases the risk of stroke. Little is known on which factors contribute to the development of AF in these patients.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Christopher Z örner, Jannik L. Pallisgaard, Anne-Marie Schjerning, Morten K. Jensen, Jacob Tønnesen, Lise D. Vestergaard, Peter Vibe Rasmussen, Gunnar Gislason, Morten L. Hansen Source Type: research

Po-05-169 ventricular scar by cardiac mri is a predictor of atrial fibrillation in hypertrophic cardiomyopathy
Atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM) increases risk of stroke and mortality. The reported prevalence of AF in HCM ranges from 18% to 28%, which is higher than the general population; even after accounting for traditional risk factors including obesity, hypertension, and age. Several factors increase risk of AF in HCM including left atrial size and the presence of ventricular obstruction. However, there is paucity of data correlating ventricular late gadolinium enhancement (LGE) to the incidence of AF in HCM.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Joseph Banno, David Fermin, Dana Marsy, Nabin Manandhar Shrestha, Richard McNamara, Jeffrey Decker, Alfred J. Albano, Jose Tan, Laura Franey, Wissam Abdallah, Christopher Madison, Renzo Loyaga Rendon, Nagib T. Chalfoun Source Type: research

Po-05-141 association of interatrial block and the development of atrial fibrillation among patients with hypertrophic cardiomyopathy
Atrial fibrillation (AF) is the most common sustained arrhythmia among those with hypertrophic cardiomyopathy (HCM), affecting 1 in 5 patients. The combination of HCM and AF is associated with an increased risk of stroke, heart failure, and mortality. Interatrial block (IAB) is a distinct electrocardiographic (ECG) pattern describing conduction delay between the right and left atria through Bachmann ’s bundle. IAB has been identified as a predictor of AF across several disease states including congestive heart failure, valvular disease, and cardiac amyloidosis.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Abdullah Alissa, Nadia Bokhari, Munther K. Homoud, Ethan Rowin, Martin S. Maron, Christopher Madias Source Type: research

Anticoagulation for Stroke Prevention in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review
Atrial fibrillation is the most common arrhythmia in patients with hypertrophic cardiomyopathy with a prevalence and incidence of 23% and 3.1% respectively. The risk of thromboembolism is high in patients with hypertrophic cardiomyopathy regardless of the CHADS2VASC score. This review includes five observational studies that focused on prevention of thromboembolism in patients with hypertrophic cardiomyopathy and atrial fibrillation. These papers evaluated and compared outcomes between patients on either warfarin or direct oral anticoagulants.
Source: Heart Rhythm - October 2, 2020 Category: Cardiology Authors: M. Farhan Nasser, Sanjay Gandhi, Robert J. Siegel, Florian Rader Source Type: research

Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Due to very high thromboembolic risk, life-long oral anticoagulation is recommended in all hypertrophic cardiomyopathy (HCM) patients with non-valvular atrial fibrillation (NVAF).1-3 We read with great interest the paper by Tsuda et al.4 who rightly emphasized the importance of HCM on thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Source Type: research

Author's reply to Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Dr. Joung and colleagues for their interests in our work.1 In our study, patients with non-valvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than NVAF patients without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study of Jung et al.,2 the stroke risk in NVAF with HCM without any other stroke risk factor was greater than that in NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all NVAF patients with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research

To the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Because of high thromboembolic risk, lifelong oral anticoagulation is recommended in all patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM).1 –3 We read with great interest the article by Tsuda et al,4 who rightly emphasized the importance of HCM in thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Tags: Letter to the Editor Source Type: research

Reply to the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Joung et  al for their interest in our work.1 In our study, patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than did patients with NVAF without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study by Jung et  al,2 stroke risk in patients with NVAF with HCM without any other stroke risk factor was higher than that in patients with NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all patients with NVAF with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research